Pacira BioSciences Announces Third Quarter Financial Results
Pacira BioSciences, Inc. is set to announce its much-anticipated third quarter financial results after U.S. markets close on an upcoming Wednesday. This is a crucial moment for the company as it continues to innovate in non-opioid pain management therapies.
Conference Call and Webcast Details
Following the earnings release, interested parties can tune into the live conference call and webcast scheduled at 4:30 p.m. ET. This provides an excellent opportunity for investors and stakeholders to gain insights directly from the company's leadership.
Participating in the Q&A Session
For those looking to actively engage in the question-and-answer session during the call, it’s essential to pre-register. Registrants will receive dial-in details, including a unique PIN, ensuring seamless participation in the discussion that follows the results announcement.
Access to Live Audio Webcast
Alongside the call, a live audio of the conference will be available online. Participants can easily find the event on Pacira's official website under the "Events" section. This accessibility reinforces Pacira's commitment to transparency and open communication with investors.
The Innovations of Pacira BioSciences
As a leader in the field, Pacira is dedicated to providing innovative, non-opioid therapies to significantly improve the lives of patients. The company's portfolio is impressive, featuring three commercial treatments designed for effective pain management.
EXPAREL®
One of the standout products is EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic. Its broad approval for various applications includes infiltration and therapeutic nerve block procedures, making it a go-to solution for postsurgical pain management.
ZILRETTA® and ioveraº®
Additionally, ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) offers relief for osteoarthritis knee pain through an extended-release intra-articular injection. Complementing this, ioveraº® delivers immediate, long-lasting, drug-free pain control through cold therapy, targeting specific nerves effectively. Together, these products illustrate Pacira's strategic approach to addressing common pain management issues.
Advancements in Gene Therapy
The company is also innovating with PCRX-201, an exciting new gene therapy aiming to tackle prevalent diseases such as osteoarthritis. This development reflects Pacira's mission to stay at the forefront of therapeutic advancements, which could dramatically change pain management methodologies.
Continued Commitment to Investors
Pacira actively encourages stakeholders to stay connected and informed about the company's progress and developments. By participating in calls and webcasts, investors can gain valuable insights into the ongoing growth and strategic plans of the company.
Investor Contacts
For any investor inquiries, they can reach out to Christian Pedetti through the dedicated contact number or email provided in their communications. It's vital for companies like Pacira to maintain open lines of communication, particularly as they navigate the complexities of financial reporting and market expectations.
Frequently Asked Questions
When will Pacira announce their third quarter financial results?
Pacira will announce its third quarter financial results after U.S. markets close on an upcoming Wednesday.
How can I participate in the earnings call?
To participate in the earnings call, please pre-register to receive dial-in information and a PIN for the Q&A session.
Will the earnings call be available as a webcast?
Yes, a live audio of the earnings call will be available as a webcast on Pacira's website.
What products does Pacira offer for pain management?
Pacira offers several products, including EXPAREL®, ZILRETTA®, and ioveraº® for non-opioid pain management solutions.
Is there any new development in Pacira's pipeline?
Yes, Pacira is advancing PCRX-201, a novel gene therapy aimed at treating osteoarthritis.
